Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of nirmatrelvir/ritonavir in hospitalized high-risk or immunocompromised patients with severe COVID-19
2022-002447-22Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nirmatrelvir/ritonavir with Placebo/ritonavir (2 arms). Primary endpoint: Change from baseline in SARS-CoV-2 RNA level in nasopharyngeal swabs at Day 5. Started Sep 2022; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002447-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002447-22.